Small molecules discovered in preclinical development studies for CLL include the glutaminase inhibitor CB-839 (telaglenastat 13) alone and in combinations with the widely used CLL drugs venetoclax, ibrutinib or MCL-1 inhibitor AZD-5991 [33]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.